The objectives of this contract are to design, develop, produce and evaluate a novel HIV vaccine based on Berna proprietary Edmonston-Zagreb measles virus (MV-EZ) vector by employing state of the art immunological, virological and molecular approaches to engineer, test and produce recombinant MV-HIV vectors and assess their ability to generate high-level, long lasting, and efficacious immune responses. The contractor possesses the key know-how and proprietary rights to form the manufacturing center for the consortium and will be responsible for the HIV vaccine process development and the production of cGMP clinical lots.
